Table 2.
DENV-2/ZIKV/WNV replication inhibitory effect.
| DENV-2 |
ZIKV |
WNV |
|||||
|---|---|---|---|---|---|---|---|
| Cpd. |
Huh7 CC50a (μM) |
IC50b (μM) | SIc | IC50 (μM) | SI | IC50 (μM) | SI |
| 10a | 20.0 | 3.4 ± 0.9 | 6 | 2.4 ± 0.3 | 8 | (1.1 ± 1.5)d | 18 |
| 10b | 8.5 | NDe | - | ND | – | ND | – |
| 10c | 5.0 | ND | - | ND | – | ND | – |
| 10d | 8.0 | ND | - | ND | – | ND | – |
| 10e | 7.5 | ND | - | ND | – | ND | – |
| 11a | 18.5 | 4.0 ± 1.02 | 5 | 2.8 ± 0.8 | 7 | (0.6 ± 0.2)d (0.6 ± 0.4)f |
28 30 |
| 11b | 12 | ND | - | ND | – | ND | – |
| 11c | 7.5 | ND | - | ND | – | ND | – |
| 11d | 8.0 | ND | – | ND | – | ND | – |
| Sofosbuvir | 200.0 | 4.7 ± 0.7 | 42 | 3.2 ± 0.7 | 62 | (1.7 ± 0.5)d (1.2 ± 0.3)f |
117 166 |
a
CC50: half-maximal cytotoxic concentration (μM).
b
IC50: half-maximal inhibitory concentration calculated through SYRA, each value is the mean of three experiments ± standard deviation (SD).
c
SI: selectivity index (SI = CC50/IC50).
d
IC50: half-maximal inhibitory concentration calculated through DYRA.
e
ND: not determined.
f
IC50: half-maximal inhibitory concentration calculated through PRA. DMSO was used as control in all cytotoxicity and antiviral assays.